3,4-methylenedioxybenzenebutanol | 97664-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 3,4-methylenedioxybenzenebutanol
• 英文别名: 4-(benzo[d][1,3]dioxol-5-yl)butan-1-ol；4-benzo[1,3]dioxol-5-yl-butan-1-ol；4-(1,3-benzodioxol-5-yl)butan-1-ol
• CAS: 97664-49-8
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: KFJKMUYYBNBSMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4-methylenedioxybenzenebutanol 生成 [1]naphthyl-carbamic acid-(4-benzo[1,3]dioxol-5-yl-butyl ester)
  参考文献：
  名称：

  Kuraoka; Sugawara, Nippon Kagaku Zasshi, 1958, vol. 79, p. 1161

  摘要：

  DOI：
• 作为产物：
  描述：

  黄樟素 在 盐酸 、 lithium aluminium tetrahydride 、 dimethyl sulfide borane 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 62.33h， 生成 3,4-methylenedioxybenzenebutanol
  参考文献：
  名称：

  Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-Adrenergic receptor blocking properties

  摘要：

  We described herein the discovery of 1-(2-(benzo[d] [1,3]dioxol-6-yl)ethyl)-4-(2-methoxyphenyl) piperazine (LASSBio-772), as a novel potent and selective alpha 1A/1D adrenoceptor (AR) antagonist selected after screening of functionalized N-phenylpiperazine derivatives in phenylephrine-induced vasoconstriction of rabbit aorta rings. The affinity of LASSBio-772 for alpha 1A and alpha 1B AR subtypes was determined through displacement of [(3)H]prazosin binding. We obtained Ki values of 0.14 nM for the alpha 1A-AR, similar to that displayed by tamsulosin (K(i) = 0.13 nM) and 5.55 nM for the alpha 1B-AR, representing a 40-fold higher affinity for alpha 1A-AR. LASSBio-772 also presented high affinity (K(B) = 0.025 nM) for the alpha 1D-AR subtype in the functional rat aorta assay, showing to be equipotent to tamsulosin (K(B) = 0.017 nM). (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.04.032

文献信息

• GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE
  申请人：SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED

  公开号：US20210115082A1

  公开（公告）日：2021-04-22

  The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

  本发明公开了一种由III式表示的糖苷化合物，以及其制备方法、组合物、用途和中间体。本发明提供的糖苷化合物具有简单的制备方法，可以显著增加VEGF-A mRNA的表达，并且在促进血管生成方面具有有效性。这为开发具有促血管生成活性的药物治疗脑梗死、脑卒中、心肌梗死和下肢缺血微循环障碍提供了可靠的保证。
• 一种糖苷类化合物的制备方法
  申请人：上海和黄药业有限公司

  公开号：CN112625073B

  公开（公告）日：2022-01-18

  本发明涉及一种糖苷类化合物的制备方法，其合成工艺步骤短，产物构型单一，选择性高，收率高，生产操作简单，设备要求低，绿色环保适合工业大规模生产。
• DERIVATIVES OF DILLAPIOL AND RELATED MONOLIGNANS AND USE THEREOF
  申请人：Arnason John Thor

  公开号：US20130012477A1

  公开（公告）日：2013-01-10

  Derivatives of dillapiol, sesamol and related monolignans having the following general formula: These compounds have synergistic properties, inhibit cytochrome P450 enzymes such as human CYP3A4, and can be used as pesticide synergists or pharmaco-enhancers. Accordingly, methods for increasing the efficacy and/or bioavailability of a pharmaceutically active agent and for increasing the potency of a pesticide are described, as are synergistic pesticidal and pharmaceutical compositions.

  dillapiol、sesamol及相关单木脂素的衍生物具有以下通用式：这些化合物具有协同作用，抑制细胞色素P450酶，如人类CYP3A4，并可用作杀虫剂增效剂或药物增强剂。因此，本文描述了增加药物活性剂的功效和/或生物利用度以及增加杀虫剂效力的方法，以及协同杀虫剂和药物组合物。
• Glycoside compound and preparation method therefor, composition, application, and intermediate
  申请人：SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED

  公开号：US11325937B2

  公开（公告）日：2022-05-10

  The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.

  本发明公开了一种由式 III 表示的糖苷化合物及其制备方法、组合物、用途和中间体。本发明提供的苷类化合物制备方法简单，能显著提高血管内皮生长因子-A mRNA的表达，有效促进血管生成。这为开发治疗脑梗塞脑中风、心肌梗塞、下肢缺血性微循环障碍等具有促血管生成活性的药物提供了可靠保证。
• [EN] METHOD FOR PREPARING GLYCOSIDE COMPOUND<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ GLYCOSIDE<br/>[ZH] 一种糖苷类化合物的制备方法
  申请人：SHANGHAI HUTCHISON PHARMACEUTICALS LTD

  公开号：WO2021139621A1

  公开（公告）日：2021-07-15

  本发明涉及一种糖苷类化合物的制备方法，其合成工艺步骤短，产物构型单一，选择性高，收率高，生产操作简单，设备要求低，绿色环保适合工业大规模生产。